Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer

NCT06328738 is registered in ClinicalTrials.gov with Enliven Therapeutics as lead sponsor.

NCT NCT06328738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06328738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Lead sponsor
Enliven Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 30, 2024
Completion date
July 31, 2028
Enrollment
275 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, her2 amplification, her2 positive solid tumors, her2-positive breast cancer, her2-positive gastric cancer